Stockscreener 앱 받기
37.75
0.91%
0.34
시간 외 거래:
37.75
전일 마감가:
$37.41
열려 있는:
$37.5
하루 거래량:
914.03K
Relative Volume:
1.16
시가총액:
$1.84B
수익:
$109.79M
순이익/손실:
$-153.49M
주가수익비율:
-11.76
EPS:
-3.2098
순현금흐름:
$-172.59M
1주 성능:
+2.58%
1개월 성능:
+40.60%
6개월 성능:
+63.14%
1년 성능:
+179.84%
1일 변동 폭
$36.67
$39.12
1주일 범위
$36.67
$39.59
52주 변동 폭
$13.26
$39.59
Urogen Pharma Ltd Stock (URGN) Company Profile
명칭
Urogen Pharma Ltd
전화
972 9 770 7601
주소
9 HA'TA'ASIYA ST, RA'ANANA
Compare URGN vs VRTX, REGN, ARGX, ALNY, RVMD
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
URGN
Urogen Pharma Ltd
|
37.75 | 1.82B | 109.79M | -153.49M | -172.59M | -3.2098 |
VRTX
Vertex Pharmaceuticals Inc
|
522.25 | 134.41B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
676.23 | 68.13B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
919.94 | 57.01B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
321.59 | 41.79B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
190.46 | 40.39B | 742.00K | -1.37B | -1.07B | -7.0731 |
Urogen Pharma Ltd Stock (URGN) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2026-04-10 | 개시 | Jefferies | Buy |
| 2025-08-19 | 개시 | Piper Sandler | Overweight |
| 2025-06-16 | 업그레이드 | H.C. Wainwright | Neutral → Buy |
| 2025-05-22 | 다운그레이드 | H.C. Wainwright | Buy → Neutral |
| 2025-04-16 | 개시 | Scotiabank | Sector Outperform |
| 2025-02-19 | 재개 | Ladenburg Thalmann | Buy |
| 2024-08-22 | 개시 | Guggenheim | Buy |
| 2023-02-08 | 다운그레이드 | Jefferies | Buy → Hold |
| 2022-04-27 | 개시 | Berenberg | Buy |
| 2020-04-16 | 재확인 | H.C. Wainwright | Buy |
| 2020-04-13 | 재확인 | H.C. Wainwright | Buy |
| 2020-01-09 | 개시 | National Securities | Neutral |
| 2019-05-30 | 개시 | JP Morgan | Neutral |
| 2019-05-29 | 개시 | Goldman | Neutral |
| 2019-01-29 | 개시 | H.C. Wainwright | Buy |
| 2018-11-08 | 재개 | Jefferies | Buy |
| 2018-04-04 | 업그레이드 | Raymond James | Mkt Perform → Outperform |
| 2018-01-02 | 개시 | Ladenburg Thalmann | Buy |
| 2017-11-15 | 재확인 | Oppenheimer | Outperform |
| 2017-11-15 | 다운그레이드 | Raymond James | Outperform → Mkt Perform |
모두보기
Urogen Pharma Ltd 주식(URGN)의 최신 뉴스
UroGen Pharma Ltd focuses on bladder cancer therapies as investors watch long-term prospects - AD HOC NEWS
URGN stock stays tied to UroGen Pharma's pipeline - AD HOC NEWS
UroGen Pharma (URGN) Stock Looks Overvalued As 257% Returns Raise The Bar - Sahm
Is UroGen Pharma a Stock to Sell After Its Chief Medical Officer Let Go of 10,000 Shares? - The Motley Fool
UroGen Pharma (URGN) Surges 4.24% as Shares Approach Key Resistance LevelCombination Correction - dars.gov.et
UroGen Pharma stock consolidates below 52-week high amid sustained bullish momentum - Traders Union
UroGen Pharma edges higher to $34.88 as leadership highlights integrity focus, UroGen Pharma - Traders Union
Urogen Pharma stock hits 52-week high at 36.12 USD By Investing.com - Investing.com South Africa
Urogen Pharma stock hits 52-week high at 36.12 USD - Investing.com
Price to book forward of UroGen Pharma Ltd. – NASDAQ:URGN - TradingView
(URGN) as a Liquidity Pulse for Institutional Tactics - Stock Traders Daily
Price to book forward of UroGen Pharma Ltd. – SWB:UR8 - TradingView
Price to sales forward of UroGen Pharma Ltd. – SWB:UR8 - TradingView
Price to book forward of UroGen Pharma Ltd. – BOATS:URGN - TradingView
UroGen settles with Teva over Jelmyto patent dispute - MSN
Enterprise value to revenue forward of UroGen Pharma Ltd. – SWB:UR8 - TradingView
Price to earnings forward of UroGen Pharma Ltd. – BOATS:URGN - TradingView
Enterprise value to EBIT forward of UroGen Pharma Ltd. – NASDAQ:URGN - TradingView
Enterprise value to EBIT forward of UroGen Pharma Ltd. – SWB:UR8 - TradingView
URGN INVESTOR ALERT: Bronstein, Gewirtz and Grossman, LLC Announc - The National Law Review
UroGen Pharma Ltd. (URGN) Investigation: Bronstein, Gewirtz & Gro - The National Law Review
Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Aga - The National Law Review
URGN SHAREHOLDER ALERT: Bronstein, Gewirtz and Grossman, LLC Anno - The National Law Review
Enterprise value to EBITDA forward of UroGen Pharma Ltd. – BOATS:URGN - TradingView
UroGen Pharma Ltd. Actuals & Estimates (NASDAQ:URGN) - TradingView
URGN Forecast — Price Target — Prediction for 2027 - TradingView
Urogen pharma CMO Mark Schoenberg sells $350,100 in shares By Investing.com - Investing.com Nigeria
Form 4 Urogen Pharma Ltd For: 24 June By Investing.com - Investing.com Australia
Urogen pharma CMO Mark Schoenberg sells $350,100 in shares - Investing.com
UroGen Pharma (URGN) CMO sells 10,000 shares in planned open-market trade - Stock Titan
UroGen Pharma (URGN) director receives new RSUs and stock option grant - Stock Titan
UroGen Pharma (URGN) director awarded 8,000 RSUs and 10,000 options - Stock Titan
UroGen Pharma (URGN) director receives 20,000 stock options at $34.99 strike - Stock Titan
[Form 4] UroGen Pharma Ltd. Insider Trading Activity - Stock Titan
UroGen Pharma (URGN) awards director RSUs and stock options - Stock Titan
Director at UroGen Pharma (NASDAQ: URGN) granted RSUs and stock options - Stock Titan
Form 144 UroGen Pharma Ltd. For: 22 June By Investing.com - Investing.com Australia
UroGen shareholders approve director insurance amendment and 2017 Plan increase - TradingView
UroGen Pharma (NASDAQ: URGN) OKs new articles and equity plan share increase - Stock Titan
Is UroGen Pharma a Stock to Sell After Its Chief Medical Officer Unloaded 5,222 Shares? - AOL.com
Non-muscle Invasive Bladder Cancer Market Dynamics to Shift During the Forecast Period (2026-2036) as Novel Targeted and Gene Therapies Enter Late-Stage Development | DelveInsight - Yahoo Finance
UroGen Pharma (URGN) Edges Higher as Stock Consolidates Near ResistanceLow Volume Node - dars.gov.et
UroGen Pharma (URGN) Form 144: Director sale of 10,000 shares for $300K - Stock Titan
UroGen Pharma StockSaturday overview of strategy and pipeline - Ad-hoc-news.de
Urogen Pharma Ltd (URGN) 재무 분석
매출
순이익
현금흐름
주당 순 이익
1.17%
2.48%
자본화:
|
볼륨(24시간):